Objective To investigate the technique of drain air, cryotherapy, and explant (DACE) of operation for superior bullous retinal detachment (SBRD). Methods In the DACE procedure, drainage and air or balanced salt soultion (BSS) injection were carried out first, with the intention of flattening the retina before localization of retinal hole, cryotherapy out of choroid and scleral buckling. Results In 42 SBRD eyes, 40 underwent the operation with DACE technique. In 23 eyes injected with BSS instead of air, 5 should be injected air due to no avail for flattening deeply retinal detachment, and 1 needed scleral buckling due to new retinal tear after DACE procedure two weeks. During the follow up, all retinae attached. Conclusions The DACE technique is very useful and effective in upper ballooned retinal detachment due to single hole or breaks localized in small area between the 10 and 2 o′clock meridiant. BSS instead of air injection can eliminate the difficulty of observation of retinal breaks from the presence of air in some cases.

Objective To establish an experimental choroidal neovascularization(CNV)model in brown norway(BN)rats by laser infusion in order to study the evolution of CNV during 3 weeks with intravitreaI injection of 1 μl(25 μg)bevacizumab,and make a preliminary investigation of the treatment effect of bevacizumab on experimental CNV. Methods Four groups of 48 BN rats were photocoagulated by krypton laser in 1 eye to induce CNV model in 1 eye,in which 4 groups received 1 μl(25 μg)bevacizumab intravitreal injection 1 week after photocoagulation and the other groups received the same volume intravitreall injection of balanced salt solution(BSS)as control.Fundus fluorescein angiography(FFA)examinations were taken on 1,2,3 week and the eyes were enucleated and processed for histopathologic examination.The areas of CNV were measured in the early phase of FFA.FⅧ-Rag protein was investigated with immunohistoehemistry and was semiquantkatively analyzed. Results The area and the leakage of CNV in bevacizumab treated BN rat eyes were obviously reduced as compared with the control group at each interval.In the treatment group,the expression of FⅧ-Rag was depressed.The examination of FⅧ-Rag and FFA verified the depression of CNV as compared with the control group at each interval.The density of treatment was lower than of control group(P＜0.01).After bevacizumab treatment for 2 weeks,the area of CNV and the expression of FⅧ-Rag were decreased[(0.920±0.634)mm2 and 35.57±10.52,respectively),as compared with the control group[(2.489±0.590)mm2 and 175.37±25.20]. Conclusions Intravitreal bevacizumab injection can inhibit the development of CNV.

BACKGROUND: Whether a combination of the nano-hydroxyapatite (nHA) scaffolds with bone morphogenetic protein-2 (BMP-2) is superimposed to promote or inhibit the bone marrow stromal stem cells, as well as its biocompatibility, remain unclear.OBJECTIVE: To observe the biocompatibility and bone formation activity of nHA/BMP-2 co-cultured with rabbit bone marrow stem cells in vitro.METHODS: Bone marrow stem cells obtained from rabbits were cultured and proliferated in DMEM medium in vitro. The cells at the third passage were inoculated into four mediums and according divided into four groups: control group, BMP-2 group, nHa group, and nHa/BMP-2 group. RESULTS AND CONCLUSION: The cell diplo-proliferation time of control group and nHa group was longer than that in BMP-2 group and nHa/BMP-2 group. The cells proliferative activity calculated by MTT assay and bone formation activity based on the alkaline phosphatase method demonstrated statistical significant difference in BMP-2 group and nHa/BMP-2 group compared with control and nHa group (P < 0.01). Experimental findings indicate that, the tissue formation of nHA/BMP-2 not only has good biocompatibility with Bone marrow stem cells, but also could bring into full play the effect of BMP-2 for promoting the proliferation, differentiation, and bone formation activity of bone marrow stem cells.

Objective To explore the relationship of stromal derived factor 1α (SDF-1α) and CD44variant isoforms (CD44v6) with progress of multiple myeloma (MM). Methods Bone marrow mononuclear cells(MNCs) and bone marrow stromal cells (BMSCs) from 24 cases of MM patients (14 cases of untreated and relapsed and 10 cases of stable MM patients) and 15 cases of subjects were investigated as potential SDF-1αand CD44v6 product. The level of SDF-1α and CD44v6 of the conditioned media from MM patients and subjects were analyzed by ELISA. Results The level of SDF-1α and CD44v6 from MNCs in untreated and relapsed MM patients [(7232.41 ± 2644.97) pg/ml and (34.34 ± 13.20) ng/ml] were significantly higher than stable MM patients [(2315.49 ± 748.29) pg/ml and (15.69 ± 5.28) ng/ml] (t =6.25, t= 7.82, P ＜0.05) and 15 subjects [(1149.52 ± 636.06) pg/ml and (4.85 ± 3.62) ng/ml] (t= 4.60, t = 7.61, P＜ 0.05). The level of SDF-1α in stable MM patients was different from healthy subjects (P ＜0.05), but the level of CD44v6 in stable MM patients was not different from controls. The level of SDF-1α and CD44v6 in stable MM patients were significantly higher than health subjects (t = 2.99, t= 4.87, P ＜0.05). The level of SDF-1α was also detected from BMSCs of MM patients. When human MM cell lines U266 were adhered to BMSCs of 9 untreated and relapsed MM patients,and added rhIL-6 to it, there was significant increase of SDF-1α, compared with BMSCs in subjects and MM patients. The expression level of SDF-lα was correlated with the level of CD44v6 (r =0.51, P =0.03). Conclusion The increase of SDF-1α (may be produced by myeloma cells and BMSCs) and CD44v6 (may be produced by myeloma cells) activity is associated with the progress or pathogenesis of MM, and may be involved with tumor invasion. The completion of these processes in vivo may need participation of myeloma cells, BMSCs, IL-6,SDF-lα and CD44v6.

Objective To investigate the clinical and CT manifestations of iatrogenic hepatic subcapsular biloma (HSB).Methods Seven cases with iatrogenic HSB confirmed by paracentesis in our hospital,and 18 reported in literatures were enrolled into this study.Their clinical and CT manifestations were retrospectively analyzed.Results Of the 25 cases,9 were secondary to laparoscopic cholecystectomy (LC),5 were secondary to percutaneous transhepatic choleductus drainage (PTCD),4 were secondary to percutaneous transhe-patic removal of bile duct stones,2 were secondary to open cholecystectomy,and 5 were secondary to other surgeries.CT showed localized or diffused hepatic subcapsular fluid collection with crescent-shaped or sac-shaped.The hepatic volume decreased and the surface was compressed in some of the cases with diffused fluid collection.Conclusion When localized or diffused hepatic subcapsular fluid collection was detected in CT imaging after liver or gallbladder surgeries (especially LC and PTCD),HSB should be considered.Paracentesis should be performed as soon as possible.

0.05).The expression of bcl-2 in sham group was significantly higher than that in GC and ADX groups(P0.05)was observed.The ratio of bax to bcl-2 in sham group was significantly lower than that in GC and ADX groups(P

The evaluation of quality of life after stroke primarily includes body,psychology, society,and the ability of activities of daily living,and they can be mainly obtained from self rating quality of life by the patients,The commonly used evaluation methods include six generic measurement scales and four updated Stroke Specific Quality of Life Scales.The latter includes the Stroke Adapted Sickness Impact Profile,the Stroke Impact Scale,Stroke Specific Quality of Life Scales,and Stroke and Aphasia Quality of Life Scale.This article reviews the generic meas- urement scales,Stroke Specific Quality of Life Scales and the various factors that influencing quality of life after stroke.

Objective To explore the time of application of hemoperfusion (HP) for the treatment of acute serious organophosphorus pesticide (ASOPP). Methods One hundred and four patients with ASOPP were randomly divided into two groups, 46 patients accepted traditional treatment(control group), 58 patients were treated with traditional treatment and HP (HP group). The patients in HP group were again divided into three groups according the different time of treatment (time of beginning HP after poisoning), the 4-8 hours group (HP-1 group, 27 patients), the 9-16 hours group (HP-2 group, 19 patients), the 17-32 hours group (HP-3 group, 12 pafients).Tbe coma period, the dosage of atropine, the time of regaining the vitality of cholinesterase, the time of hospitalization and the rate of fatality and curing among groups were observed. Results The coma period, the dosage of atropine, the time of regaining the vitality of cholinesterase, the time of hospitalization and the rate of fatality of the HP group were less than those of the control group (P<0.05). Compared with HP-1 group, the eoma period, the dosage of atropine, the time of regaining the vitality of eholinesterase and the time of hospitalization of the HP-2 group and the HP-3 group were higher (P<0.05), but the difference of the rate of fatality and curing between the HP-1 group and the other HP groups was not statistically significant (P>0.05). The difference of all of the above indicators between HP-2 group and HP-3 group was not statistically significant (P>0.05). Conclusion Application of hemoperfusion among 4-32 hours after poisoning for the treatment of ASOPP can improve the efficacy of therapy, and the efficacy of application of hemoperfusion among 4-8 hours is the best.

According to the work goals and tasks determined by edition outline of the Chinese Pharmacopoeia 2025 Edition, the Chinese Pharmacopoeia 2025 has been completed. Among them, 52 new pharmaceutical excipients monographs have been added, and the total number has reached 387. 245 pharmaceutical excipients monographs have been revised, of which 109 monographs have only textual revisions and 136 monographs have substantive revisions. This article focuses on the general framework and the main characteristics of the standards of pharmaceutical excipients in the Chinese Pharmacopoeia 2025, which can contribute to accurately understand and utilize the standards in Chinese Pharmacopoeia.